Opinion|Videos|June 19, 2024
Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
Donna Catamero, ANP-BC, OCN, CCRC, presents the case of a 77-year-old patient who experienced ICANS following CAR T-cell therapy and describes the role of the ICE score.
Advertisement
Episodes in this series
In this episode, Donna Catamero, ANP-BC, OCN, CCRC, presents the case of a 77-year-old patient who experienced ICANS following CAR T-cell therapy and describes the role of the ICE score.
Advertisement
Related to this article
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
5